Nucleus Genomics is a next-generation direct-to-consumer genetic testing platform that aims to provide genetic risk scores for various diseases and traits using whole-genome sequencing (WGS) technology.
The company plans to deliver consumer genetic test kits and offer customizable disease and trait reports. Individuals can also obtain further insights by uploading their already genotyped DNA from platforms such as 23andMe, Ancestry, or via a genetic testing kit to Nucleus Genomics' platform. The company also integrates genetic information with non-genetic information to calculate the absolute risk scores for people with diseases.
In July 2022, the company launched the beta version of its consumer-facing testing platform.
Funding and Financials
In July 2022, the company raised USD 14 million in a seed-plus funding round led by Seven Seven Six. The new funds were allocated toward expanding its scientific and engineering team, developing its computational capabilities, and establishing the physical infrastructure required for scaling its WGS technology.
Also, in July 2022, the company acquired the open-source software tool Impute.me for an undisclosed amount, which was to be integrated into Nucleus Genomics’ own genetic analysis platform to enhance the quality of its reports further.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.